About Drizzle Health
Drizzle Health helps food producers and laboratories prepare full batches for diagnostic testing. Its inline system sits in wash water or a production line, processes an entire batch within minutes and sends the output to existing PCR tests. The company also developed Medupi, a portable tuberculosis screening device for community health workers and primary care centers. Medupi was designed to return immediate results so clinicians could start treatment and follow-up sooner.
Drizzle Health operates from Baltimore. Digvijay Singh is its co-founder and chief executive officer, overseeing product, design and commercialization. Bonolo Mathekga is co-founder and chief technology officer, overseeing engineering, clinical work and operations.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Sep 2, 2026 | Nov 10, 2026 | $600,000target not set | 1 | $600K | Options, Securities on exercise, The securities being offered are simple agreements for future equity (SAFE)Rule 506(b) | Form D ↗ |
| Nov 20, 2024 | Nov 26, 2024 | $500,000target not set | 1 | $500K | Options, Securities on exercise, The securities being offered are simple agreements for future equity (SAFE)Rule 506(b) | Form D ↗ |
| Total, two offerings | $1,100,000 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Why Investors Backed Drizzle Health
Drizzle Health builds inline equipment that prepares complete wash-water or production batches for PCR testing. The investment thesis rests on improving incoming samples rather than replacing laboratory tests. Clinical validation and field deployment remain the central execution risks.
The problem it targets
Drizzle's view is that a diagnostic test is limited by the sample entering it. Billions of tests run each year across food production, clinical laboratories and water systems. In 2021, tuberculosis caused almost 1.6 million deaths annually, while only 56% of cases were bacteriologically confirmed. Some patients waited four to six weeks for testing.
What the product does
Medupi's cartridge followed existing tuberculosis testing pathways and also worked with sputum smear microscopy. Drizzle expected its device network to map outbreaks and hot areas in real time. Those maps could help government programs direct follow-up and control local transmission. The system focused on community health workers serving rural, peri-urban and urban populations in India.
Progress so far
By August 2021, Drizzle had partnerships in India and a clinical study ready, though COVID-19 had delayed it. The Medupi reader had completed laboratory proof-of-concept testing with artificial samples and was undergoing further tests and industrial design. Indian research and state health officials invited site studies after reviewing the cartridge. The team planned 100 to 1,000 patient tests within a year and expected full development in early 2022. It projected 10 million to 30 million annual screenings beginning in 2023.
We wrote this summary from public statements by Drizzle Health and its investors. It is not investment advice.
Leadership Team
Executive officers and directors listed on Drizzle Health's Form D filed Nov 10, 2026.
